Sept 8 (Reuters) - Concordia Healthcare Corp CXR.TO :
* To acquire Amdipharm Mercury Limited (AMCO) for US$3.5 billion creating a
global platform to facilitate future growth
* Says deal immediately accretive to Concordia adjusted EPS, with more than 35%
accretion expected in the first full year
* Deal amount to be paid through a cash, common shares of Concordia, and
performance-based earn-out payable in cash
* On pro forma basis, the combined company is expected to achieve revenue of
US$870 million - $920 million for full year 2015
* On pro forma basis, combined company is expected to achieve adjusted EBITDA
of $510 million - $540 million for full year 2015
* Deal purchase price will consist of cash of about £800 million (about $1.2
billion), 8.49 million common shares of Concordia
* Deal purchase price will include assumption of approximately US$1.4 billion
amco net debt
* Entered into agreement with Cinven, and certain funds managed by it to
acquire Amdipharm Mercury Limited
* Says deal anticipated to be financed through a combination of term loans,
bonds and a public offering of equity securities
* Following deal-close, co will own a 100% in amco, cinven will hold expected
19.9% ownership in Concordia on non-diluted basis
* Goldman, Sachs, Credit Suisse (SIX:CSGN), RBC Capital, Jefferies to provide credit
facilities and bridge commitments of up to $4.3 billion
* Deal approved by board of directors of both Concordia and Cinven, and is
"strongly supported" by the AMCO management team
* Source text for Eikon ID:nPn2DrqZB
* Further company coverage CXR.TO